Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease

Neurology

Volumn 46, Issue 3, 1996, Pages 796-801

  Ahlskog, J E ^a,c   Uitti, R J ^b   Low, P A ^a   Tyce, G M ^a   O'Brien, J F ^a   Nickander, K K ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CYSTEINYLDOPA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MALONALDEHYDE; MONOAMINE OXIDASE B INHIBITOR; OXYGEN RADICAL; PERGOLIDE; SELEGILINE;

ADULT; AGED; ARTICLE; AUTOOXIDATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE METABOLISM; HUMAN; HUMAN TISSUE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SERUM;

EID: 0030010238     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.3.796     Document Type: Article

References (43)

1. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(Suppl 3):32-37.
2. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32: 804-812.
3. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
4. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(Suppl 3):50-54.
5. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
6. Olanow CW. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov Disord 1993;8:S1-S7.
7. Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798.
8. Ward CD. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994;57:217-220.
9. Parker W Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989;26:719-723.
10. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992;4:27-34.
11. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992;32:782-788.
12. Bindoff LA, Birch-Machin M, Cartlidge NE, Parker W Jr, Turnbull DM. Mitochondrial function in Parkinson's disease. Lancet 1989;2:49.
13. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker W Jr, Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 1991;104:203-208.
14. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 1991;30:332-339.
15. Cardellach F, Marti MJ, Fernandez-Sola J, et al. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 1993;43:2258-2262.
16. Kilinc A, Yalcin AS, Yalcin D, Taga Y, Emerk K. Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson's disease. Neurosci Lett 1988;87:307-310.
17. Kalra J, Rajput AH, Mantha SV, Chaudhary AK, Prasad K. Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Mol Cell Biochem 1992;112:181-186.
18. Flint A. The skin in Parkinson's disease. Prim Care 1977; 4:475-480.
19. Fornstedt B, Rosengren E, Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 1986;25:451-454.
20. Fornstedt B. Role of catechol autooxidation in the degeneration of dopamine neurons. Acta Neurol Scand Suppl 1990; 129:12-14.
21. Carlsson A, Fornstedt B. Possible mechanisms underlying the special vulnerability of dopaminergic neurons. Acta Neurol Scand Suppl 1991;136:16-18.
22. Carlsson A, Fornstedt B. Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease. Neurology 1991;41(Suppl 2):50-51.
23. Ahlskog JE, Uitti RJ, Low PA, et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord 1995;10:566-573.
24. Therasse J, Lemonnier F. Determination of plasma lipoperoxides by high-performance liquid chromatography. J Chromatogr 1987;413:237-241.
25. Fornstedt B, Bergh I, Rosengren E, Carlsson A. An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid. J Neurochem 1990;54:578-586.
26. Devalon ML, Miller TD, Squires RW, Rogers PJ, Bove AA, Tyce GM. Dopa in plasma increases during acute exercise and after exercise training. J Lab Clin Med 1989;114:321-327.
27. Hunter LW, Rorie DK, Yaksh TL, Tyce GM. Concurrent separation of catecholamines, dihydroxyphenylglycol, vasoactive intestinal peptide and neuropeptide Y in superfusate and tissue extract. Anal Biochem 1988;173:340-352.
28. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435.
29. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203.
30. Mena MA, Pardo B, Casarejos MJ, Fahn S, Garcia de Yebenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7:23-31.
31. Sato Y, Hotta N, Sakamoto N, Matsuoka S, Ohishi N, Yagi K. Lipid peroxide level in plasma of diabetic patients. Biochem Med 1979;21:104-107.
32. Noberasco G, Odetti P, Boeri D, Maiello M, Adezati L. Malondialdehyde (MDA) level in diabetic subjects. Relationship with blood glucose and glycosylated hemoglobin. Biomed Pharmacother 1991;45:193-196.
33. Collier A, Rumley A, Rumley AG, et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992;41:909-913.
34. McMurray J, McLay J, Chopra M, Bridges A, Belch JJ. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;65:1261-1262.
35. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991;65:245-248.
36. Ciuffetti G, Corea L, Mannarino E, Mercuri M, Lombardini R, Santambrogio L. Leucocytes and free radicals in stable angina pectoris. Jpn Heart J 1992;33:145-157.
37. Ciuffetti G, Mercuri M, Mannarino E, et al. Free radical production in peripheral vascular disease. A risk for critical ischaemia? Int Angiol 1991;10:81-87.
38. Baldi E, Burra P, Plebani M, Salvagnini M. Serum malondialdehyde and mitochondrial aspartate aminotransferase activity as markers of chronic alcohol intake and alcoholic liver disease. Ital J Gastroenterol 1993;25:429-432.
39. Cedarbaum JM, Silvestri M, Clark M, Harts A, Kutt H. L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease. Clin Neuropharmacol 1990;13: 29-35.
40. Hovevey-Sion D, Kopin IJ, Stull RW, Goldstein DS. Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology 1989;28:791-797.
41. Koulu M, Scheinin M, Kaarttinen A, et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-255.
42. Baronti F, Davis TL, Boldry RC, Mouradian MM, Chase TN. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992;42:541-544.
43. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County Project. Neurology 1993;43:1918-1926.